| Name | Title | Contact Details |
|---|---|---|
Quin Martin |
General Counsel | Profile |
We are a trusted partner and advisor to executives, founders and funders – bringing strategic and tactical knowledge, expertise and tools that help them solve problems, overcome challenges and reclaim time. We provide a tailored suite of cross-functional services designed to empower and enable brands to grow, drive revenue, operate with ease and transform company culture.
Based in the Pacific Northwest of the United States, SSC North America is a hypercar manufacturer that specializes in limited production vehicles for elite clientele around the world. In 2007, the SSC Ultimate Aero, a high performance hypercar produced by SSC, legitimized the companys standing as a leading player in the worldwide hypercar market by officially becoming the "Worlds Fastest Production Car" as witnessed and recorded by Guinness World Records. The Ultimate Aero achieved an average two-way speed of 256.18 mph, making SSC one of only 26 manufactures in world history to hold this prestigious title. Today, SSC North America is in the late development stages of the next world record breaking hypercar, the Tuatara. With the Ultimate Aeros record setting achievements and the world renowned performance brought by the next generation Tuatara, SSC North America stands firmly as a great American hypercar company, and will continue to lead innovation in the hypercar market.
At the Gibraltar International Bank, we believe that empowering you to manage your money easily is key. We have invested in state-of-the-art technology and online banking so that you can conduct your banking in whatever situation you may find yourself. There really is so much that we can offer both personal and corporate clients. To discover what we can do for you, just get in touch using the details below. We would love to hear from you. Phone +350 (200) 13900 Email gibraltar@gibintbank.gi
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.